Established in 1989, Stason Industrial Corporation entered the US generics market with the formation of Stason Pharmaceuticals, Inc. in 1994. While venturing into NDA development, we continue to develop these products through our global network of affiliates, partners and distributors.
In 2008, we launched our Brand Division when we obtained exclusive commercialization rights to novel proprietary compounds in the area of oncology. In 2015, we acquired an NDA. For more information Click Here
In 2014, we established our sales & marketing division, which has captured a significant market share for each product. We expect to launch several products per year, including authorized generics, injectables, and 505(b)(2)s.